V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240014462 | 240008769 | 1.76 | 84.4 | Palliative (P) | 2015-07-07 | 2015-07-08 | CARMUSTINE + THIOTEPA | N | N | 240015521 | PMITCEBO-R |
| 240014463 | 240008772 | 0 | 59.1 | Disease modification (D) | 2017-09-13 | 2017-09-25 | NHL 2003 Gp C COPADM 1 | N | N | 240015633 | ENZALUTAMIDE |
| 240014464 | 240008774 | 1.7 | 98.6 | Curative (C) | 2018-05-07 | 2018-06-23 | Irinotecan + Modified De Gramont | N | N | 240015692 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240014465 | 240012687 | 0 | 69 | Curative (C) | 2017-08-31 | 2017-08-31 | Irinotecan + Modified De Gramont | 2 | N | 240016012 | ALEMTUZUMAB |
| 240014466 | 240008777 | 1.71 | null | Disease modification (D) | 2017-07-13 | 2017-07-18 | CRIZOTINIB | N | N | 240016111 | TOPOTECAN |
| 240014467 | 240014528 | 1.81 | 104.3 | Curative (C) | 2018-09-09 | 2018-09-14 | Triple / Double Intrathecal Therapy | 2 | N | 240016330 | R CODOX M |
| 240014468 | 240012691 | 1.68 | 50 | Palliative (P) | null | 2016-08-31 | ETOPOSIDE | null | null | 240016360 | TOPOTECAN |
| 240014469 | 240008784 | 1.65 | 47.9 | Curative (C) | 2018-05-17 | 2018-05-25 | CVP | 02 | N | 240016409 | PILOT TRIAL |
| 240014470 | 240012693 | null | 43.2 | T | 2014-11-20 | 2015-03-31 | CVP | 02 | N | 240016504 | CAV |
| 240014471 | 240008787 | 1.74 | null | Curative (C) | 2016-07-27 | 2016-09-10 | Imatinib 400mg | null | N | 240016548 | IDELALISIB + RITUXIMAB |
| 240014472 | 240008789 | 1.68 | 77.6 | Curative (C) | 2016-05-16 | 2016-06-10 | NHL 2003 Gp C M2 & 4 | 2 | N | 240017029 | IPILIMUMAB + NIVOLUMAB |
| 240014473 | 240014532 | 1.72 | null | Palliative (P) | 2016-02-11 | 2016-02-25 | CHOEP | N | N | 240017071 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 240014474 | 240012697 | 1.85 | 87.7 | Curative (C) | 2018-02-03 | 2018-02-03 | Enzalutamide | 02 | Y | 240017201 | TRIPLE INTRATHECAL |
| 240014475 | 240008794 | 1.63 | null | null | null | 2017-07-19 | CISPLATIN + FLUOROURACIL | N | N | 240017293 | IMATINIB |
| 240014476 | 240008797 | null | 68.3 | Curative (C) | 2014-04-16 | 2014-04-30 | Capecitabine (21days) + Carboplatin | N | N | 240017472 | AML19 TRIAL |
| 240014477 | 240008798 | null | null | Curative (C) | 2016-06-26 | 2016-07-05 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 240017540 | CISPLATIN + FLUOROURACIL |
| 240014478 | 240008800 | null | 92.4 | Curative (C) | 2017-08-16 | 2018-01-25 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 02 | N | 240017716 | AML17 TRIAL |
| 240014479 | 240008804 | 1.8 | null | Palliative (P) | null | 2018-01-12 | Imatinib 400mg | N | N | 240017785 | GEMCITABINE + OXALIPLATIN |
| 240014480 | 240008806 | null | 78 | Palliative (P) | 2016-08-12 | 2016-08-22 | Cytarabine intrathecal | N | N | 240018081 | IELSG32 TRIAL |
| 240014481 | 240008807 | 1.8 | 64.8 | Disease modification (D) | 2018-04-29 | 2018-04-30 | ETOPOSIDE | 2 | N | 240018110 | CODOX M |
| 240014482 | 240012705 | 1.77 | null | null | 2014-09-16 | 2014-11-01 | BORTEZOMIB + THALIDOMIDE | N | N | 240018318 | ALEMTUZUMAB |
| 240014483 | 240012705 | 1.57 | 43.2 | Curative (C) | 2014-07-01 | 2014-10-27 | IVE | N | N | 240018318 | FLUOROURACIL + MITOMYCIN + RT |
| 240014484 | 240008812 | 1.57 | 82.5 | Curative (C) | 2018-10-10 | 2018-10-16 | ETOPOSIDE + IFOSFAMIDE | N | N | 240018715 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 240014485 | 240008813 | 1.66 | 52.5 | Palliative (P) | 2013-06-11 | 2013-06-14 | ETOPOSIDE | N | null | 240018886 | VEDEX |
| 240014486 | 240012708 | 1.79 | 90 | Palliative (P) | 2018-11-03 | 2018-11-03 | IVE | N | N | 240019224 | R CODOX M |
| 240014487 | 240012709 | 1.78 | 70.4 | Curative (C) | 2014-11-07 | 2014-11-07 | Cytarabine HD + Methotrexate HD | 2 | null | 240019309 | DOCETAXEL + NINTEDANIB |
| 240014488 | 240015929 | 1.56 | null | Neo-adjuvant (N) | 2018-01-30 | 2018-01-30 | Cyclophosphamide + Etoposide (PO) | N | N | 240019353 | PILOT TRIAL |
| 240014489 | 240008820 | null | 84.4 | Curative (C) | 2016-04-01 | 2016-07-06 | Vinorelbine IV | N | N | 240019431 | CYTARABINE + METHOTREXATE |
| 240014490 | 240008821 | 1.65 | 64.55 | Curative (C) | 2015-04-19 | 2015-06-13 | Irinotecan + Modified De Gramont | N | null | 240019486 | IRINOTECAN + MDG |
| 240014491 | 240008825 | 1.65 | 70.2 | null | 2020-02-14 | 2020-02-14 | AML16 DA 3+10 | N | N | 240019900 | TRIPLE INTRATHECAL |
| 240014492 | 240008828 | 1.68 | 68.4 | Curative (C) | 2018-01-26 | 2018-02-12 | Triple Intrathecal | N | N | 240019983 | REMODL TRIAL |
| 240014493 | 240008829 | 1.64 | null | Curative (C) | 2018-08-19 | 2018-08-19 | RUXOLITINIB | N | null | 240020241 | LIPOSOMAL DOXORUBICIN |
| 240014494 | 240008831 | 1.69 | 72 | Curative (C) | 2016-12-26 | 2016-12-29 | REMODLB TRIAL | N | Y | 240020325 | VINORELBINE |
| 240014495 | 240008834 | 1.82 | 72.5 | Curative (C) | 2015-08-18 | 2015-09-04 | REMODLB TRIAL | N | N | 240020386 | CYTARABINE INTRATHECAL |
| 240014496 | 240008837 | 1.75 | 77.5 | Curative (C) | 2018-10-24 | 2018-10-24 | AML17 TRIAL | 2 | N | 240020387 | IVE-R |
| 240014497 | 240008841 | null | 55.9 | Palliative (P) | 2019-06-01 | 2019-06-08 | UKALL14- Maintenance | N | null | 240020675 | CYTARABINE HD + METHOTREXATE HD |
| 240014498 | 240008842 | 1.58 | null | Disease modification (D) | 2019-05-07 | 2019-05-12 | ATG + Busulfan + Fludarabine | N | N | 240020689 | CODOX M |
| 240014499 | 240008844 | 1.52 | 62 | Disease modification (D) | 2017-12-19 | 2017-12-24 | PEMBROLIZUMAB | Y | null | 240020689 | CARBOPLATIN + DOCETAXEL |
| 240014500 | 240008847 | 1.54 | null | Curative (C) | 2016-07-27 | 2016-08-07 | Topotecan (intravenous) | null | null | 240020798 | R CODOX M |
| 240014501 | 240008849 | 1.48 | 45.8 | Palliative (P) | 2015-08-14 | 2015-08-21 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 240020856 | NAB-PACLITAXEL |
| 240014502 | 240012728 | 1.68 | 76 | Palliative (P) | 2017-05-08 | 2017-05-11 | TOPOTECAN | 2 | N | 240020870 | CAPECITABINE |
| 240014503 | 240008853 | 1.39 | 76.4 | Palliative (P) | 2017-07-11 | 2017-07-11 | DA-EPOCH-R | Y | N | 240020924 | MITOXANTRONE |
| 240014504 | 240008854 | 1.53 | 68.2 | Adjuvant (A) | 2016-06-29 | 2016-07-06 | Triple Intrathecal | 02 | N | 240021063 | CISPLATIN + MITOMYCIN |
| 240014505 | 240008857 | 1.7 | 87.7 | Curative (C) | 2016-06-13 | 2016-06-22 | BCG Intravesical | N | N | 240021157 | IVE + METHOTREXATE |
| 240014506 | 240014549 | null | 91 | Palliative (P) | 2016-04-03 | 2016-09-01 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | 240021189 | CYTARABINE HD + METHOTREXATE HD |
| 240014507 | 240008862 | 1.52 | 70.2 | Palliative (P) | 2016-01-28 | 2016-01-28 | ICE-R | N | N | 240021253 | VEDEX |
| 240014508 | 240008865 | 1.84 | 73.3 | Curative (C) | 2018-11-14 | 2018-12-12 | IELSG 32 TRIAL | N | N | 240021267 | IVAC |
| 240014509 | 240008866 | 1.81 | null | Curative (C) | 2014-03-09 | 2014-04-04 | Triple / Double Intrathecal Therapy | null | null | 240021369 | CTD |
| 240014510 | 240014551 | 1.79 | 65.4 | Curative (C) | 2018-10-04 | 2018-10-04 | CARMUSTINE + THIOTEPA | N | N | 240021606 | IVE |
| 240014511 | 240008868 | 1.59 | null | Curative (C) | 2017-04-28 | 2017-04-29 | CHOEP | N | N | 240021767 | R-EPOCH |